Domperidone: review of pharmacology and clinical applications in gastroenterology
- PMID: 17488253
- DOI: 10.1111/j.1572-0241.2007.01255.x
Domperidone: review of pharmacology and clinical applications in gastroenterology
Abstract
Domperidone is a dopamine-2 receptor antagonist. It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine. Unlike metoclopramide, it does not cause any adverse neurological symptoms as it has minimal penetration through the blood-brain barrier. It thus provides an excellent safety profile for long-term administration orally in the recommended doses. Domperidone is widely used in many countries and can now be officially prescribed to patients in the United States by an investigational new drug application for the treatment of gastroparesis and any condition causing chronic nausea and vomiting. In view of this additional clinical exposure of domperidone to a new generation of gastroenterologists and other specialists, the purpose of this timely review is to revisit the pharmacology, clinical application, and safety profile of this beneficial medication.
Comment in
-
Dosage and drug interactions of domperidone.Am J Gastroenterol. 2008 Apr;103(4):1049. doi: 10.1111/j.1572-0241.2007.01772_12.x. Am J Gastroenterol. 2008. PMID: 18397438 No abstract available.
Similar articles
-
Dosage and drug interactions of domperidone.Am J Gastroenterol. 2008 Apr;103(4):1049. doi: 10.1111/j.1572-0241.2007.01772_12.x. Am J Gastroenterol. 2008. PMID: 18397438 No abstract available.
-
Domperidone: a peripherally acting dopamine2-receptor antagonist.Ann Pharmacother. 1999 Apr;33(4):429-40. doi: 10.1345/aph.18003. Ann Pharmacother. 1999. PMID: 10332535 Review.
-
Domperidone, a new dopamine antagonist.CMAJ. 1986 Sep 1;135(5):457-61. CMAJ. 1986. PMID: 3527396 Free PMC article. Review.
-
A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis.Am J Gastroenterol. 1999 May;94(5):1230-4. doi: 10.1111/j.1572-0241.1999.00456.x. Am J Gastroenterol. 1999. PMID: 10235199 Clinical Trial.
-
[Current role of antidopaminergic drugs in pediatrics].Pediatr Med Chir. 2000;22(1):1-7. Pediatr Med Chir. 2000. PMID: 11387760 Review. Italian.
Cited by
-
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.Br J Clin Pharmacol. 2009 Mar;67(3):333-40. doi: 10.1111/j.1365-2125.2008.03310.x. Epub 2008 Sep 19. Br J Clin Pharmacol. 2009. PMID: 19220275 Free PMC article. Clinical Trial.
-
New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.Inflammopharmacology. 2024 Oct;32(5):3119-3161. doi: 10.1007/s10787-024-01499-8. Epub 2024 Jul 9. Inflammopharmacology. 2024. PMID: 38980576 Review.
-
Endoscopic botox injections in therapy of refractory gastroparesis.World J Gastrointest Endosc. 2015 Jul 10;7(8):790-8. doi: 10.4253/wjge.v7.i8.790. World J Gastrointest Endosc. 2015. PMID: 26191343 Free PMC article. Review.
-
Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis.Clin Gastroenterol Hepatol. 2019 Jul;17(8):1489-1499.e8. doi: 10.1016/j.cgh.2018.10.050. Epub 2018 Nov 4. Clin Gastroenterol Hepatol. 2019. PMID: 30404035 Free PMC article.
-
The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying.Dig Dis Sci. 2009 Jan;54(1):57-62. doi: 10.1007/s10620-008-0335-6. Epub 2008 Jul 4. Dig Dis Sci. 2009. PMID: 18600456
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical